Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)

NCT02684370 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02684370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02684370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2016
Completion date
September 30, 2017
Enrollment
560 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis